If the Trump administration uses an interim final rule to put in place the president’s plan to base Medicare reimbursement on international drug prices, drug makers will surely sue, drug lobbyists say. A lawsuit might benefit President-elect Joe Biden by blocking the policy and freeing up the Biden administration to work on its own administrative measures to lower drug prices. Although President Donald Trump announced in 2018 his plan to create an International Pricing Index, HHS did not propose a...